share_log

Here's What We Like About Baotou Dongbao Bio-TechLtd's (SZSE:300239) Upcoming Dividend

Here's What We Like About Baotou Dongbao Bio-TechLtd's (SZSE:300239) Upcoming Dividend

以下是我們對包頭東寶生物技術有限公司(深圳證券交易所代碼:300239)即將派發的股息的喜愛之處
Simply Wall St ·  05/27 19:19

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) is about to go ex-dividend in just 3 days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is important because any transaction on a stock needs to have been settled before the record date in order to be eligible for a dividend. Thus, you can purchase Baotou Dongbao Bio-TechLtd's shares before the 31st of May in order to receive the dividend, which the company will pay on the 31st of May.

有些投資者依靠分紅派息來增加財富,如果你是其中之一,你可能會想知道,東寶生物(SZSE:300239)將在3天內進行除息。除息日是股東資格登記日前1個工作日,而股東資格登記日是公司記載股東資格的截止日,以便有資格獲得股息支付。除息日很重要,因爲股票的任何交易在股東資格登記日前需要清算,才有資格獲得股息。因此,你可以在5月31日之前購買東寶生物的股票以接收將於5月31日支付的股息。

The company's next dividend payment will be CN¥0.022 per share, and in the last 12 months, the company paid a total of CN¥0.022 per share. Calculating the last year's worth of payments shows that Baotou Dongbao Bio-TechLtd has a trailing yield of 0.4% on the current share price of CN¥5.13. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to check whether the dividend payments are covered, and if earnings are growing.

該公司下一個分紅派息爲人民幣0.022元每股,過去12個月,該公司每股支付了總計人民幣0.022元的分紅派息。計算過去一年的股息支付金額表明,以目前人民幣5.13元的股價計算,東寶生物的股息率爲0.4%。分紅派息是許多股東的重要收入來源,但企業的健康狀況對於維持這些分紅派息至關重要。因此,我們需要檢查股息支付是否有保障以及收益是否增長。

If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. Baotou Dongbao Bio-TechLtd has a low and conservative payout ratio of just 11% of its income after tax. Yet cash flow is typically more important than profit for assessing dividend sustainability, so we should always check if the company generated enough cash to afford its dividend. Thankfully its dividend payments took up just 30% of the free cash flow it generated, which is a comfortable payout ratio.

如果一家公司支付的分紅派息金額超過其收益,則分紅派息可能變得不可持續。東寶生物的分紅派息比率相當低和保守,僅佔稅後收入的11%。但是,對於評估分紅派息是否持續,現金流通常比利潤更重要,因此我們應始終檢查公司是否產生足夠的現金來支付其股息。幸運的是,其分紅派息僅佔其產生的自由現金流的30%,這是一個舒適的分紅派息比率。

It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.

看到股息既有盈利也有現金流的覆蓋是令人鼓舞的。這通常表明股息是可持續的,只要收益沒有急劇下降。

Click here to see how much of its profit Baotou Dongbao Bio-TechLtd paid out over the last 12 months.

點擊此處以查看東寶生物在過去12個月中支付了多少利潤。

historic-dividend
SZSE:300239 Historic Dividend May 27th 2024
SZSE:300239歷史分紅,2024年5月27日

Have Earnings And Dividends Been Growing?

收益和股息一直在增長嗎?

Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings decline and the company is forced to cut its dividend, investors could watch the value of their investment go up in smoke. It's encouraging to see Baotou Dongbao Bio-TechLtd has grown its earnings rapidly, up 21% a year for the past five years. Earnings per share have been growing very quickly, and the company is paying out a relatively low percentage of its profit and cash flow. This is a very favourable combination that can often lead to the dividend multiplying over the long term, if earnings grow and the company pays out a higher percentage of its earnings.

每股收益穩步增長的公司通常是最佳的分紅股,因爲他們通常會更容易增加每股分紅派息。如果收益下降,公司被迫削減分紅派息,則投資者可能會看到其投資價值化爲烏有。東寶生物迅速增長其收益率,過去5年年增長率爲21%。每股收益增長非常迅速,公司支付的利潤和現金流相對較低。這是一個非常優越的組合,如果收益增長並且公司支付的收益百分比更高,通常會導致分紅派息在長期內增加。

Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Baotou Dongbao Bio-TechLtd has seen its dividend decline 5.8% per annum on average over the past 10 years, which is not great to see. It's unusual to see earnings per share increasing at the same time as dividends per share have been in decline. We'd hope it's because the company is reinvesting heavily in its business, but it could also suggest business is lumpy.

衡量公司股息前景的另一個關鍵方法是通過衡量其歷史股息增長率來進行。東寶生物過去10年每股分紅派息平均下降了5.8%,這是不太好的情況。隨着每股收益增加,而每股分紅派息下降,這種現象是不尋常的。我們希望這是因爲公司正在大量再投資,但也可能表明公司的業務波動不定。

To Sum It Up

總結一下

From a dividend perspective, should investors buy or avoid Baotou Dongbao Bio-TechLtd? It's great that Baotou Dongbao Bio-TechLtd is growing earnings per share while simultaneously paying out a low percentage of both its earnings and cash flow. It's disappointing to see the dividend has been cut at least once in the past, but as things stand now, the low payout ratio suggests a conservative approach to dividends, which we like. There's a lot to like about Baotou Dongbao Bio-TechLtd, and we would prioritise taking a closer look at it.

從分紅的角度來看,投資者應該買入或避免東寶生物的股票?東寶生物每股收益增長並且同時支付的利潤和現金流百分比都相對較低,這很棒。過去分紅派息已經被削減過至少一次,但從目前情況來看,低分紅比率表明分紅派息管理層採取了一種保守的方法,我們也很喜歡這種方法。關於東寶生物,有很多值得關注的地方,我們會優先深入了解它。

So while Baotou Dongbao Bio-TechLtd looks good from a dividend perspective, it's always worthwhile being up to date with the risks involved in this stock. Our analysis shows 1 warning sign for Baotou Dongbao Bio-TechLtd and you should be aware of it before buying any shares.

雖然包頭東寶生物科技股份有限公司從股息角度來看不錯,但了解這隻股票涉及的風險總是值得的。我們的分析顯示包頭東寶生物科技股份有限公司存在1個警示信號,購買任何股票前請注意。

A common investing mistake is buying the first interesting stock you see. Here you can find a full list of high-yield dividend stocks.

一個常見的投資錯誤是購買你看到的第一個有趣的股票。在這裏,您可以找到高股息股票的完整列表。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論